ClinicalTrials.gg
CompletedNCT04055506Updated Jun 18, 2020

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

A Phase 1 interventional study of BMS-986165 and Ritonavir in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The Study of Cytochrome P450 1A2 Induction by Ritonavir on the drug effects of BMS-986165 in Healthy Participants

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal renal function at screening as evidenced by an estimated (GFR) > 80 mL/min/1.732 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.
  • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic onadotropin) within 24 hours prior to the start of study treatment.
  • of 18.0 kg/m2 to 32.0 kg/m2, inclusive, and body weight ≥ 50 kg, at screening.

Exclusion criteria

Exclusion Criteria:

  • Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.
  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, , or clinical laboratory determinations beyond what is consistent with the target population.
  • Prisoners or participants who are involuntarily incarcerated
  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Combination Therapy

    Drug: BMS-986165 · Drug: Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986165

    Time frame: Day 1

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration of BMS-986165

    Time frame: Day 1

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time in BMS-986165

    Time frame: Day 1

  4. Maximum observed plasma concentration of BMS-986165 in combination with steady-state ritonavir

    Time frame: Day 15

  5. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration of BMS-986165 in combination with steady-state ritonavir

    Time frame: Day 15

  6. Area under the plasma concentration-time curve from time zero extrapolated to infinite time in BMS-986165 in combination with steady-state ritonavir

    Time frame: Day 15

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: initial dose up to day 29

  2. vital signs of blood pressure

    Time frame: initial dose up to day 29

  3. Vital signs of body temperature

    Time frame: initial dose up to day 29

  4. Vital signs of respiratory rate

    Time frame: initial dose up to day 29

  5. Number of Clinically significant changes in lab assessment of blood serum

    Time frame: initial dose up to day 29

  6. Number of Clinically significant changes in the lab assessment of blood

    Time frame: initial dose up to day 29

  7. Number of Clinically significant changes in the lab assessment of urine

    Time frame: initial dose up to day 29

07

Study locations

1 site
  • PRA Health Sciences - Salt Lake
    Salt Lake City, Utah 84124, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Sep 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2019
First posted
Aug 13, 2019
StartActual
Aug 14, 2019
Primary completionActual
Sep 21, 2019
CompletionActual
Sep 21, 2019
Last update
Jun 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04055506
Responsible party
Sponsor
First posted
Aug 13, 2019
Start date
Aug 14, 2019
Primary completion
Sep 21, 2019
Completion
Sep 21, 2019
Last update
Jun 18, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion